We're dealing with the courts, and lots of unfortunate mistakes come in trying to divine what the courts will do. Both companies are facing something only a few weeks away; it could be good or bad for either.

Drug stocks have remained relatively cheap, and you'll notice that since interest rates are of little importance to the major pharmaceutical companies ... there's a run toward some of the defensive characteristics of drug stocks.